WS #12548
Danaher plunges 14% on guidance cut; GM beats Q2 estimates and raises guidance; Schwab stock recovers after boosting revenue guidance; SpaceX rises on ARK Invest purchase and earnings date announcement. Novo Nordisk sues Eli Lilly for false advertising in weight-loss drug ads; Merck's Lipfendra approval expected to disrupt PCSK9 market.
Corporate Earnings and Guidance
Danaher plunges 14% on guidance cut; GM beats Q2 estimates and raises guidance; Schwab stock recovers after boosting revenue guidance; SpaceX rises on ARK Invest purchase and earnings date announcement.
Novo Nordisk sues Eli Lilly for false advertising in weight-loss drug ads; Merck's Lipfendra approval expected to disrupt PCSK9 market.